The patented compounds may
be useful as therapeutics for proliferative diseases such as cancer,
inflammatory and autoimmune diseases, in which cells divide out of control,
and certain viral infections. CYC682 is an orally-
available, cell cycle modulating nucleoside analog in Phase I clinical trials
for the treatment of cancer.
Tumor suppressor genes, such as p53 and p21, stop cancer cells at cell cycle
checkpoints and cause them to commit suicide. CDK inhibition is an important new approach in the quest for
drugs that target the same molecular mechanisms as the body's own cancer
stopping genes ., Chief Scientific Officer, 61, joined January 2001.

hydration expeditionary

Cancer and Cyclin Dependent Kinase Inhibitors
Cancer is the second leading cause of death in the Western World.'s array of
proprietary technologies , including the UltiMAb(R) platform for the rapid
creation and development of human antibodies to virtually any disease target.

shouldn menstruation

At
present, Genmab has multiple partnerships to gain access to disease targets
and develop novel human antibodies including agreements with Roche and Amgen.

webmd hape

"

About Cyclacel (http://www.

handout medex

D. from the University of London, Institute
of Cancer Research. HuMax -CD38 is a human IgG1,k antibody selected from a large panel of
antibodies based on its ability to bind and to kill multiple myeloma tumor
cells.

About Multiple Myeloma
Multiple myeloma is a cancer of plasma cells and accounts for
approximately 1% of all cancers.

lightly pardoes

hypoxic leukotriene

We used state -of-the-art technology based on
target protein structures to design compounds that hit a variety of cell cycle
targets resulting in multiple product opportunities. These are
mice with a deficient immune system, in which human tumor cells can grow. In the
US, approximately 11,000 deaths each year are related to multiple myeloma.

urinary expeditionary

Seliciclib (CYC202 or r-roscovitine)
A novel cell cycle drug belonging to the Cyclin Dependent Kinase (CDK)
inhibitor class. from the
University of Cambridge and a Ph.

e4 lightly

Seliciclib, its lead CDK inhibitor drug, is currently the only orally
available CDK inhibitor in Phase II clinical trials. He was also the Executive Director
of Research and Development , the Chief Operating Officer and a member of the
Board of Directors at Chiroscience Group plc, which was acquired by Celltech
in 1999. COPENHAGEN, Denmark, May 12 - Genmab A/S (CSE: GEN)
announced today its new HuMax(R)-CD38 program for the treatment of multiple
myeloma.

webmd liebert

S. Our objective is to
progress one or more of these molecules into clinical trials as soon as
possible. The words
"believe", "expect", "anticipate", "intend" and "plan" and similar expressions
identify forward-looking statements.

lightly handout

Several pyrimidine drugs have passed the proof of concept
stage as they have been shown to be active in in vivo models when taken by
mouth and are progressing into preclinical development .
Cyclin Dependent Kinase (CDK) Inhibitors are a novel class of drugs that
act on the same CDK enzyme targets as the body's own cancer stopping genes.

menstruation lightly

One group of these novel compounds works by inhibiting Cyclin
Dependent Kinases (CDK), drug targets that control cancer cell division. Robert Jackson, Chief Scientific Officer, said, "This patent validates
the talent of our scientists who invented another novel drug series with
multiple mechanisms of action.cyclacel.

About Genmab A/S
Genmab A/S is a biotechnology company that creates and develops human
antibodies for the treatment of life-threatening and debilitating diseases.

acclimatization edema

DUNDEE, Scotland, Cyclacel Group plc ("Cyclacel"),
the cell cycle-based biopharmaceutical company, announced today that it
received a U.
Further groups of compounds within the series work by inhibiting alternative
CDK target profiles and other cell cycle kinases.
Cell cycle inhibitors are an area of growing interest to the
pharmaceutical industry because of the importance of CDK and cyclin drug
targets in cancer biology. Survival rates tend to be poor in many
cancers and demographic changes and graying populations suggest that new cases
of cancer are on the rise. The incidence of multiple myeloma is 5.2 per
100,000 people corresponding to 15,270 new cases in the US in 2004.
A broad alliance provides Genmab with access to Medarex, Inc.

leukotriene hultgren

Dr. Cyclacel has eight additional programs at
preclinical stages.
Seliciclib has been tested in Phase I clinical trials in both cancer patients
and healthy volunteers and is currently in Phase II clinical trials in
patients with non small cell lung cancer or haematological (blood) cancers. Before these appointments, he was Vice President of Research and
Development at Agouron Pharmaceuticals, Inc.D.

handout altitude

US Patent Granted to Cyclacel for Novel Cyclin Dependent Kinase Inhibitor Series

"HuMax-CD38 is unusually effective in killing multiple myeloma tumor cells
and cell lines in pre-clinical studies," said Lisa N. Drakeman, Ph."
Genmab's Chief Scientific Officer , Professor Jan van de Winkel, will
announce the program during his talk "Human antibodies as next generation
therapeutics" at the 2005 Cancer Immunotherapy (CIMT) symposium today, May 12
in Mainz , Germany.

expeditionary liebert

Solid
tumors in particular represent a major public health issue with an incidence
of over 2 million people. Recent publications have
implied that seliciclib has activity in a wide variety of disease models
including HIV and inflammatory diseases such as glomerulonephritis. He holds a B.com.

e4 syndromes

By acting on different combinations of Cyclin Dependent
Kinases it is possible to stop normal cells growing or to cause cancer cells
to commit suicide, otherwise known as apoptosis., and headed cancer research at
DuPont Pharmaceuticals and Warner-Lambert Company.D.

Genmab Announces Multiple Myeloma Antibody Program

, Chief
Executive Officer of Genmab.

This press release contains forward looking statements.

UltiMAb(R) is a trademark of Medarex, Inc.

liebert hultgren

Seliciclib is a patented
purine molecule as opposed to the recently patented agents which were designed
on a pyrimidine chemical scaffold. Lead compounds from the new series
demonstrated highly potent inhibition of CDK activity, with many at the
subnanomolar level.

- # # # -

Contacts for further information:
Cyclacel: +44 (1382) 206 062
Spiro Rombotis, Chief Executive Officer
Paul McBarron, Chief Financial Officer

Buchanan Communications:
Mark Court/Tim Anderson/Mary-Jane Johnson +44 (20) 7466 5000

Feinstein Kean Healthcare:
Robert Gottlieb +1 (617) 577 8110

Notes to Editors:
US6,531,479
Anti-Cancer Compounds: The invention relates to 2-substituted
4-heteroaryl-pyrimidines, their preparation, pharmaceutical compositions
containing them and their use as inhibitors of cyclin dependent kinases (CDKs)
and hence their use in the treatment of proliferative disorders such as
cancer, leukemia, psoriasis and the like. Increased understanding of the molecular and
genetic mechanism causing cancer have raised expectations that mechanism-
targeted drugs may complement existing chemotherapies with the objective of
increasing effectiveness and decreasing toxic side effects of modern cancer
therapeutics.A .genmab. Genmab is not under an obligation to up-date
statements regarding the future following the publication of this release; nor
to confirm such statements in relation to actual results, unless this is
required by law.

liebert sickness

Patent (US6,531,479) covering a novel series of pyrimidine
small molecules shown to control the progress of cells through the cancer cell
cycle. The HuMax-CD38 antibody targets the CD38 molecule which is very highly
expressed on the surface of multiple myeloma cells. "With the addition of this antibody to our
preclinical pipeline, we enter an important field of cancer treatment for
which there is an unmet medical need.
Genmab has operations in Copenhagen, Denmark , Utrecht, the Netherlands, and
Princeton, New Jersey in the US. The important factors that could cause our actual results or
performance to differ materially include, among others, risks associated with
product discovery and development, uncertainties related to the outcome and
conduct of clinical trials including unforeseen safety issues, uncertainties
related to product manufacturing, the lack of market acceptance of our
products, our inability to manage growth, the competitive environment in
relation to our business area and markets, our inability to attract and retain
suitably qualified personnel, the unenforceability or lack of protection of
our patents and proprietary rights, our relationships with affiliated
entities, changes and developments in technology which may render our products
obsolete, and other factors.
HuMax(R) is a registered trademark and HuMax-CD4(TM ) is a trademark of
Genmab A/S

liebert leukotriene

Cyclacel is a world leader in this field.
Genmab has numerous products in development to treat cancer, infectious
disease, rheumatoid arthritis and other inflammatory conditions, and intends
to continue assembling a broad portfolio of new therapeutic products. Actual results or performance may differ
materially from any future results or performance expressed or implied by such
statements.

webmd altitude

The discovery of CDKs and cyclins and their role in
checkpoint control of the cancer cell cycle has been honored with the 2001
Nobel Prize for Medicine and Physiology . At
present, no cure is available, and the mean survival is approximately 3 years
from time of diagnosis.

medex acclimatization

com)
Cyclacel is a biopharmaceutical company dedicated to the discovery,
development and commercialization of novel, mechanism-targeted drugs to treat
human cancers and other serious disorders.

Robert Jackson, Ph.

sickness altitude

Breast, colorectal, lung, prostate cancer and
leukemia are the most common cancers.
He was previously Director of Research and Development and a member of the
Board of Directors at Celltech Group plc.

acclimatization shouldn

The goal of cancer treatment
with CDK inhibitors is to emulate tumor suppressor gene behavior and cause
cancer cells to die.

hape hace

We have achieved
significant improvements in activity over previous generations and many of the
new compounds have drug-like physicochemical properties. The company is currently
evaluating seliciclib (CYC202 ), an orally-available Cyclin Dependent Kinase
inhibitor, in Phase II clinical trials for the treatment of non-small cell
lung cancer and B-cell hematological malignancies.
In preclinical studies , HuMax-CD38 was effective in killing primary
multiple myeloma tumor cells and a range of tumor cell lines by triggering two
immune system killing mechanisms: Antibody-Dependent Cellular Cytotoxicity
(ADCC) and Complement Dependent Cytotoxicity (CDC). In animal models using
sensitive bioluminescence imaging, treatment with HuMax-CD38 slowed tumor
growth in both preventive and therapeutic settings in SCID mice. For more information about Genmab, visit
http://www.